Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Updates in Hair Loss Management: Minoxidil, JAK Inhibitors, and Emerging Therapies
Description
The talk reviewed recent advances in hair loss management across androgenetic alopecia, alopecia areata, and scarring alopecias. Low-dose oral minoxidil is increasingly used off-label, with emerging extended-release and sublingual formulations designed to maintain therapeutic follicle levels while reducing cardiac risk; phase 3 data for oral extended-release minoxidil (VDPHL) and sublingual minoxidil are expected soon. Combination therapy with oral minoxidil plus 5-alpha reductase inhibitors showed greater hair-density improvement than minoxidil alone, and the topical stem-cell–targeting agent PP405 showed promising early phase 2 results with phase 3 underway. For alopecia areata, the speaker highlighted three FDA-approved oral JAK inhibitors, including the newest agent deuruxolitinib, which works quickly, requires CYP2C9 genotyping, is dosed twice daily, and may work better when started earlier in less extensive scalp hair loss. In scarring alopecias, low-dose doxycycline appeared as effective as higher doses with fewer adverse effects, supporting use of subantimicrobial dosing. Finally, a Delphi consensus supported low-dose oral minoxidil as adjunctive therapy in several hair-loss conditions, including scarring alopecias, alopecia areata, telogen effluvium, and chemotherapy-induced alopecia.
View moreConclusions
- Low-dose oral minoxidil is increasingly supported as a broadly useful off-label therapy for multiple types of hair loss, including androgenetic, alopecia areata, telogen effluvium, and several scarring alopecias.
- New oral and sublingual minoxidil formulations may improve convenience, efficacy, and cardiovascular tolerability by sustaining follicular exposure while limiting peak systemic effects.
- Combination oral therapy for androgenetic alopecia, especially low-dose oral minoxidil plus a 5-alpha-reductase inhibitor, appears more effective than minoxidil alone without clearly increasing side effects.
- The topical agent PP405 shows early promise for pattern hair loss by reactivating dormant follicles, but it remains investigational pending larger phase 3 confirmation.
- Alopecia areata treatment options have expanded substantially with multiple FDA-approved JAK inhibitors, giving clinicians more targeted oral therapies than before.
- Deuruxolitinib appears to act quickly and may work better when started earlier or in patients with less extensive scalp involvement.
- For inflammatory scarring alopecias, low-dose doxycycline seems to provide similar benefit to high-dose doxycycline with fewer adverse effects, supporting lower-dose regimens in practice.
- Consensus and emerging evidence suggest low-dose oral minoxidil should be considered as adjunctive supportive therapy across several hair-loss conditions rather than only pattern hair loss.
- Nohria A, et al. J Am Acad Dermatol, 2025; 92, 1159-1161.
- Akiska YM and colleagues in JAMA Dermatology, 2025.